Drug firm Aspen Pharmacare has offered to pay the U.K.’s National Health Service (NHS) £8 million (U.S. $9.7 million) as part of a deal with the country’s competition regulator following suspicions that the company paid rival firms to delay marketing a vital medicine so it could retain its market dominance.
It is the first time the regulator has secured a direct payment for the NHS as a result of anti-competitive behavior by one of its drugs suppliers.
